Investigating new treatments for lung scarring in idiopathic pulmonary fibrosis
Official title: Screening of novel compounds through the reversal of gene expression in idiopathic pulmonary fibrosis
Funded at Henry Ford Health + Michigan State University Health Sciences · NIH-11040233 · Data updated 2026-11-12
This study is looking for new ways to help people with idiopathic pulmonary fibrosis (IPF) by finding compounds that could change how certain genes work in the lungs, which might lead to better treatments for this tough lung disease.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Henry Ford Health + Michigan State University Health Sciences NIH-funded |
| Lab location | 1 site (East Lansing, United States) |
| Project start | April 1, 2025 |
| Project end | March 31, 2026 |
| Funding year | 2025 |
| Award (this year) | $542,402 |
| NIH project number | 1R61HL177451-01 |
| Project ID | NIH-11040233 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adults diagnosed with idiopathic pulmonary fibrosis who are seeking new treatment options.
✕Less likely to help
Patients with other forms of lung disease or those who do not have idiopathic pulmonary fibrosis may not benefit from this research.
What this research studies
This research focuses on understanding idiopathic pulmonary fibrosis (IPF), a serious lung condition characterized by scarring of lung tissue. The team aims to identify novel compounds that can reverse the gene expression changes associated with IPF, potentially leading to new therapies. By utilizing advanced techniques like single-cell RNA sequencing, they will analyze the small airways in the lungs to uncover the roles of different cell types in the disease. This approach may help in developing effective treatments that go beyond current options, which only slow disease progression.
Why it matters
Potential benefit: If successful, this research could lead to groundbreaking therapies that effectively reverse lung fibrosis and improve survival rates for patients with IPF.
How similar studies have gone: While there have been advancements in understanding IPF, this specific approach using novel compounds and single-cell analysis is relatively novel and has not been extensively tested.
Where this research is happening
-
Henry Ford Health + Michigan State University Health Sciences
East Lansing, United States Active
Researchers
- Principal investigator: Li, Xiaopeng — Henry Ford Health + Michigan State University Health Sciences
- Study coordinator: Li, Xiaopeng
Related research
Other NIH-funded projects on the same topics.
-
Repurposing Pyrvinium as an Inhaled Therapy for Idiopathic Pulmonary Fibrosis
A patient-friendly look at a project trying to use an existing drug, pyrvinium, as an inhaled treatment option for idiopathic pulmonary fibrosis (IPF).
-
Screening new compounds to reverse gene signatures in IPF lungs
A researcher hopes to find compounds that reverse harmful gene changes in the lungs of people with idiopathic pulmonary fibrosis (IPF).
-
Unraveling IPF subtypes to guide prognosis and therapy
This grant aims to identify different IPF subtypes in the lung to improve how we predict outcomes and tailor treatments for people with IPF.
-
Novel antibody therapy to treat idiopathic pulmonary fibrosis
A small business gig is developing a targeted antibody drug (VSR-H5) to treat idiopathic pulmonary fibrosis in patients, aiming for better safety and effectiveness than current medicines.
-
Repurposing Vonoprazan as an inhaled therapy for IPF
A high-profile NIH grant is testing whether an existing drug, vonoprazan, can be inhaled to slow or reverse lung fibrosis in people with idiopathic pulmonary fibrosis (IPF).
-
Proteomic profile of IPF progression to help tailor treatments
A study will look for blood protein patterns that predict how IPF lung disease will progress in patients.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.